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Abstract
Background: Sarcomatoid cancer is defined by the World Health Organization as a category of non-small cell lung
cancers with sarcoma or sarcoma-like differentiation. They are characterized by poor prognosis and resistance to
conventional chemotherapy. However, the mutational profile of sarcomatoid cancer remains yet to be elucidated.
Sarcomatoid cancers are usually biphasic tumors composed of carcinomatous and sarcomatous components, but
the evolutional development of sarcomatoid cancer is controversial.
Case presentation: We present an illustrative case of sarcomatoid cancer composed of three different histological
areas. Targeted sequencing of 53 lung cancer-related genes was performed in each component and their
phenotypic changes were correlated with stepwise addition of genetic changes.
Conclusion: Sarcomatous change of carcinoma occurs in the case of sarcomatoid cancer, and phenotypic changes
to sarcomatoid cancer are associated with the addition of mutation patterns and derived from poorly differentiation
tumor.
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Background
Sarcomatoid carcers are rare malignant biphasic tumors
composed of carcinomatous and sarcomatous compo-
nents. However, it is still unclear whether the carcinomat-
ous or sarcomatous component develops first, or whether
they develop simultaneously from adjacent areas. We re-
cently encountered a patient who underwent surgery for
sarcomatoid cancer that was composed of three different
histological areas. To examine whether the different histo-
logical components resulted from genetic divergence, tar-
geted sequencing was performed in each histological
component. Herein, we report the case findings and the
genomic analysis of sarcomatoid differentiation.
Case presentation
The patient was a 54-year-old man. He complained of
hemosputum, and chest X-ray showed a mass shadow in
the right upper lung field (Fig. 1a). He had a history of
smoking 20 cigarettes per day for 30 years. Chest com-
puted tomography revealed an irregularly-shaped mass
in segment 1 of the right lung (Fig. 1b). Bronchoscopic
biopsy led to a diagnosis of adenocarcinoma.
Under a diagnosis of lung cancer (cT2aN0M0), he
underwent right upper lobectomy and lymph node dissec-
tion. Bilateral legs had been swelling preoperatively, which
subsided spontaneously after the surgery. Pleural lavage
cytology led to a diagnosis of disseminated adenocarcin-
oma (pT2aN0M1a, stage IV); histopathological analysis
showed that tumor was composed of three different histo-
logical areas; portion A: well-differentiated adenocarcin-
oma, portion B: poorly differentiated adenocarcinoma,
portion C: sarcomatoid cancer, and portion B was a major
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Fig. 1 Radiological and histopathological findings. a A chest radiograph showing a mass in the right upper lung field. b A chest computed tomography
scan showing a mass with an irregular surface in the right upper lobe. c Gross examination showing a solid tumor (diameter, 5 cm) with internal bleeding.
d-g Topographic presentation of the cut surface shows three different components; portion A: well-differentiated adenocarcinoma (e), portion B: poorly
differentiated adenocarcinoma (f), and portion C: sarcomatoid cancer (g). The ratio of the area occupied by these 3 components, i.e. well-differentiated
adenocarcinoma: poorly differentiated adenocarcinoma: sarcomatoid cancer, is 15: 80: 5. Yellow, light blue and red denote the area of well-differentiated
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Fig. 2 Genomic analyses. a Heat map for the mutations in each cancer component and ctDNA detected in plasma. Column next to heatmap
shows the mutated genes and amino acid changes. AF, allele fraction b Validation of somatic mutations by Sanger sequencing. Representative
image of read alignments visualized with IGV of targeted sequencing data (left) and Sanger sequencing data (right). The arrow shows the position
of the variant. Well, well-differentiated adenocarcinoma; Poor, poorly differentiated adenocarcinoma; Sarco, sarcomatoid carcinoma
Goto et al. BMC Cancer  (2017) 17:65 Page 2 of 5
component (Fig. 1c-g). As the sarcomatoid cancer compo-
nent accounted for less than 10% of the entire tumor area,
the cancer did not meet the diagnostic criteria for pleo-
morphic carcinoma. To examine whether different histo-
logical components resulted from genetic divergence,
tumor cells of each different histological area were col-
lected from formalin-fixed paraffin-embedded tissues by
using laser capture microdissection (Fig. 1d-g). A panel
targeting the exon of 53 lung cancer-associated genes was
established in-house, as we previously reported [1–4].
Subsequently targeted sequencing of those 53 lung
cancer-related genes was performed. The sequencing data
were processed using standard Ion Torrent Suite software
running on a Torrent Server (Thermo Fisher Scientific).
Variants calling were performed using an Ion Reporter
Server System (Thermo Fisher Scientific), and peripheral
blood DNA was used as a control to detect somatic muta-
tions in tumours using filtration of “confident somatic var-
iants” in a Tumour-Normal pair pipeline [4, 5]. This study
was approved by the institutional review board, and the
patient provided written informed consent. In total, there
were 26 mutations found in the cancer (Fig. 2a and
Additional file 1: Table S1), and mutations with an allele
fraction ≥30% were determined as significant mutations
(Table 1). Common missense mutations in TP53 and
KRAS genes were detected in the portion A, B and C
(Table 1, Fig. 2a). These mutations were validated by
Sanger sequencing (Fig. 2b). The positions and patterns of
the amino acid changes and base-pair substitutions in
those co-mutations were consistent (Table 1).
For further inference of phylogenies and estimation of
evolutionary distances, the Neighbor-Joining method
was implemented to cluster the nonsilent mutations and
the phylogenetic tree was constructed (Fig. 3a and b) [6].
The ‘ape’ and ‘phangon’R (3.2.3 on linux) packages were
utilized for these analyses. As a result, sarcomatoid com-
ponent clusters together with poorly differentiated
adenocarcinoma and that cluster segregates away from
well-differentiated adenocarcinoma (Fig. 3a). From the
phylogenetic tree, it can be inferred, under the
Table 1 Mutation analysis in different histological areas
Histological area Gene Mutation Position Ref Variant in tumor AF
Portion A: well diff. Adeno TP53 p.V118F chr17:7578461 C A 47%
KRAS p.G12V chr12:25398284 C A 30%
Portion B: poorly diff. Adeno KRAS p.G12V chr12:25398284 C A 97%
TP53 p.V118F chr17:7578461 C A 86%
Portion C: sarcomatoid TP53 p.V118F chr17:7578461 C A 70%
KRAS p.G12V chr12:25398284 C A 52%
The table listed somatic mutations with an allele fraction ≥30%
chr chromosome, Ref reference sequence, AF allele fraction
Fig. 3 Phylogenetic analyses. a Cluster analysis of the point mutations in each cancer component. The mutation data were standardized and
presented as a heat map. Column next to heatmap shows the mutated genes and amino acid changes. b The phylogenetic tree was constructed
by an approach using the bootstrap. Branch lengths correlates with the number of nucleotide substitutions. Abbreviations: Non mut, non-
mutated cells; Well, well-differentiated adenocarcinoma; Poor, poorly differentiated adenocarcinoma; Sarco, sarcomatoid carcinoma
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assumption of normal cells without any mutations being
roots, that well-differentiated adenocarcinoma first
branched off from the roots, and that another branch
evolved through poorly differentiated adenocarcinoma
into sarcomatoid carcinoma (Fig. 3b). According to the
branch length, which indicates the evolutionary distance,
the distance between the poorly differentiated adenocar-
cinoma and the sarcomatoid carcinoma is relatively
short.
Postoperative adjuvant chemotherapy was performed,
but the patient developed lung and brain metastases and
died of cancer 5 months postoperatively.
Discussion
Sarcomatoid carcinomas are carcinomas with sarcoma
or sarcoma-like features. They are rare entities and
are characterized by poor prognosis and resistance to
conventional chemotherapy or radiotherapy. On
evaluating the mutational profile of sarcomatoid
cancer, Fallet et al. reported that the most frequently
detected mutations were KRAS, EGFR, TP53, STK11,
NOTCH1, NRAS, and PIK3CA [7].
In our case, comparative genetic analysis of differ-
ent histological areas revealed intratumoral homogen-
eity for some mutations. These concordant mutations
across different sites reinforced the hypothesis that a
single cell clone evolved and progressed later by
addition of other mutations into different histological
phenotypes, involving epithelial-to-mesenchymal tran-
sition. In portions B and C of the tumor, TP53 and
KRAS mutations were found at high allelic fractions
over 70%, which strongly indicates the incidence of
allelic losses or amplifications of these genes.
Some hypotheses have been proposed regarding the
development of sarcomatoid carcinoma, such as: (i)
simultaneous malignant transformation of epithelial el-
ements and stroma, (ii) malignant transformation of
cancer-derived stroma, (iii) sarcomatous change of car-
cinoma, (iv) carcinomatous change of sarcoma. With
regard to the development of sarcomatoid carcinoma in
the present case, the mutation analysis results indicated
the occurrence of a sarcomatous change.
From the phylogenetic analyses, it can be concluded
that stepwise addition of genetic changes caused the
sarcomatous change in this cancer. Sarcomatous
cancer is reported to be resistant to conventional
chemotherapy or radiation therapy and to show poor
prognosis. Reflecting on these observations, the muta-
tions responsible for those phenotypic changes may be
relate to worse clinical outcomes. Further understand-
ing of the molecular pathology of sarcomatoid cancer
may help in selection of sarcomatoid cancer patients
for newly developed molecular-targeted therapies.
Conclusions
The different histological components in lung cancer re-
sult from genetic divergence. Sarcomatous change of car-
cinoma occurs in the case of sarcomatoid or pleomorphic
cancer. Phenotypic changes to sarcomatoid cancer are as-
sociated with the addition of mutation patterns.
Additional file
Additional file 1: Table S1.Somatic mutations identified by targeted
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